Hosted on MSN3mon
Frontline EGFR/VEGF Inhibition Slows Advanced EGFR-Positive Lung Cancer
Adding the VEGF inhibitor ramucirumab (Cyramza) to the EGFR inhibitor osimertinib (Tagrisso) slowed progression of untreated EGFR-positive non-small cell lung ... in the first-line setting in ...
pharmaphorum4y
Price cut wins NICE OK for AZ’s Tagrisso in untreated lung cancer
UK cost-effectiveness watchdog NICE has changed its stance on AstraZeneca’s Tagrisso as a first-line therapy for non-small cell lung cancer ... with the T790M resistance mutation subtype.
Hosted on MSN12mon
Janssen seeks EMA approval of RYBREVANT for NSCLC
The asset is intended to be used along with lazertinib for the first-line treatment ... has immune cell-directing activity. It acts on tumours with activating and resistance EGFR mutations ...